Axcelis Technologies IncAxcelis announced a planned US$35 million ion implantation manufacturing facility in Pyeongtaek, Korea, a capacity/capex investment.

Axcelis Technologies has announced a planned US$35 million ion implantation manufacturing facility in Pyeongtaek, Korea. The capacity move comes as the company's shares have risen 3.5% over one day and 7.4% over seven days, though the stock is down 11% over 30 days and 34% over 90 days, while year-to-date it is up 31.4% and its five-year total shareholder return stands at 127.4%. Axcelis last closed at $113.15, below the $161 fair value cited in the most-followed analyst narrative, which sees the stock as 30% undervalued, while a Simply Wall St discounted cash flow model estimates future cash flow value at just $10.79 per share. The bullish case rests on ongoing R&D and next-generation Purion platform enhancements driving customer engagement in advanced node processes such as trench and super junction devices, but also leans heavily on China exposure and silicon carbide adoption trends that could surprise negatively. Simply Wall St produced the analysis.
Axcelis Technologies IncAxcelis announced a planned US$35 million ion implantation manufacturing facility in Pyeongtaek, Korea, a capacity/capex investment.